CTNM
Contineum Therapeutics, Inc.
Contineum Therapeutics, Inc. (CTNM) has 4 SEC Form 4 filings (12 transaction rows) in the rolling window, disclosed by 3 distinct insiders. Most recent filing: Jul 2, 2026.
The most active filer is Chief Scientific Officer Lorrain Daniel S. with 3 filings. Insiders have net sold $983K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Carmine N. Stengone
- Employees:41
- HQ:San Diego, CA, US
- IPO:2024-04-05
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$983K
reported sales (SEC code S)
Unique Insiders
3
in the rolling window
Market Cap
$348.8M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Scientific Officer | Sale | 28,826 | $462K | Jul 2 | SEC ↗ | |
| Chief Scientific Officer | Sale | 8,353 | $132K | Jul 2 | SEC ↗ | |
Watkins TimFirst filing | CMO & Head of Development | Sale | 10,833 | $174K | Jul 1 | SEC ↗ |
Stengone Carmine N.First filing | CEO and President | Sale | 10,000 | $160K | Jul 1 | SEC ↗ |
Lorrain Daniel S.First filing | Chief Scientific Officer | Sale | 4,170 | $55K | May 1 | SEC ↗ |
Related companies
Contineum Therapeutics, Inc. is in the Healthcare sector.